SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001437749-23-001440
Filing Date
2023-01-20
Accepted
2023-01-20 16:53:10
Documents
13
Period of Report
2023-01-10
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K cbli20230120_8k.htm   iXBRL 8-K 26313
  Complete submission text file 0001437749-23-001440.txt   154866

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA stab-20230110.xsd EX-101.SCH 3601
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE stab-20230110_def.xml EX-101.DEF 11160
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE stab-20230110_lab.xml EX-101.LAB 14898
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE stab-20230110_pre.xml EX-101.PRE 11261
7 EXTRACTED XBRL INSTANCE DOCUMENT cbli20230120_8k_htm.xml XML 2485
Mailing Address 2537 RESEARCH BOULEVARD, SUITE 201 FORT COLLINS CO 80526
Business Address 2537 RESEARCH BOULEVARD, SUITE 201 FORT COLLINS CO 80526 (888) 613-8802
Statera Biopharma, Inc. (Filer) CIK: 0001318641 (see all company filings)

IRS No.: 200077155 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-32954 | Film No.: 23541618
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences